Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Trending Topics Diabetes Fierce 50 Special Report Awards Gala Resources Fierce Events Industry Events Webinars Podcasts Whitepapers Survey Events Subscribe Subscribe Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Trending Topics Diabetes Fierce 50 Special Report Awards Gala Resources Fierce Events Industry Events Webinars Podcasts Whitepapers Survey Events Subscribe Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us Biotech Covidien wraps spinoff of drug unit By John Carroll Jul 1, 2013 11:05am Covidien ($COV) has completed the spinoff of its pharma unit, Mallinckrodt. Mallinckrodt has a small pipeline of novel and generic drugs as well as imaging agents. It is trading on the New York Stock Exchange under the symbol MNK. Report